REGISTERED
on 22 Mar 2022
Last Applicant/ Owned by
405 Eagleview Boulevard
Exton
PA
19341
Serial Number
90498064 filed on 29th Jan 2021
Registration Number
6675782 registered on 22nd Mar 2022
Filing Basis
1. use application currently
Disclaimer
NO DATA
CASTLE CREEK BIOSCIENCES
Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of preparations and Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific research and development, namely, research and development of pharmaceutical and medical preparations for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of therapeutics and procedures for skin diseases, connective tissue diseases, arthritis and autoimmune diseases; scientific research and development of preparations and therapeutics
First Use Date in General
29th Feb 2020
First Use Date in Commerce
29th Feb 2020
Mark Details
Serial Number
No 90498064
Mark Type
No Service Mark
Attorney Docket Number
No 189105-5017
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 22nd Mar 2022 | REGISTERED-PRINCIPAL REGISTER |
| 04th Jan 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 04th Jan 2022 | PUBLISHED FOR OPPOSITION |
| 15th Dec 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 01st Dec 2021 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| 30th Nov 2021 | ASSIGNED TO LIE |
| 30th Nov 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 19th Nov 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 18th Nov 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 18th Nov 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |